Jooeun Kang

Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device‐specific LVAD management

T. Motomura, Carlo R. Bartoli, Jooeun Kang, 2020, Journal of cardiac surgery.

Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.

Jessica L. Howard, M. Acker, T. Motomura, 2017, The Annals of thoracic surgery.

Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.

F. Kallel, M. Acker, P. Atluri, 2016, The Journal of thoracic and cardiovascular surgery.

Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.

M. Acker, P. Atluri, Carlo R. Bartoli, 2015, JACC. Heart failure.

Clinical and In Vitro Evidence That Subclinical Hemolysis Contributes to LVAD Thrombosis.

Jessica L. Howard, M. Acker, C. Bermudez, 2017, The Annals of thoracic surgery.

A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage.

D. Harrison, S. Goleva, Hana A. Itani, 2017, JCI insight.

Clinical and In Vitro Evidence That Left Ventricular Assist Device–Induced von Willebrand Factor Degradation Alters Angiogenesis

M. Acker, C. Bermudez, P. Atluri, 2018, Circulation. Heart failure.

Continuous-Flow LVAD Support Causes a Distinct Form of Intestinal Angiodysplasia

M. Acker, C. Bermudez, P. Atluri, 2017, Circulation research.